BPI 442096
Alternative Names: BPI-442096Latest Information Update: 18 Nov 2022
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Nov 2022 Phase-I clinical trials in Solid tumours in China (unspecified route) Before November 2022 (Betta Pharmaceuticals pipeline, November 2022)
- 18 Nov 2022 Phase-I clinical trials in Solid tumours in USA (unspecified route) Before November 2022 (Betta Pharmaceuticals pipeline, November 2022)
- 24 May 2022 The US FDA accepts IND application for a phase I trial of BPI 442096 in Solid tumors in USA